“ALL 硬”- K药强势“ALL-IN”消化道肿瘤( 六 )


[12] Finn RS, Ryoo B-Y, Merle P, et al. Pembrolizumab as second-linetherapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: arandomized, double-blind, phase III trial. J Clin Oncol 2020; 38:193-202.
[13] Kudo M et al., Pembrolizumab as Second-Line Therapy for AdvancedHepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3KEYNOTE-240 Trial. Liver Cancer. Published online: April 27, 2021, DOI:10.1159/000515553
[14]Ikeda M, Sung MW, Kudo M, et al. A phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. JCO. 2018;36:4076. doi:10.1200/JCO.2018.36.15_suppl.4076
[15] Andrew X. Zhu et al. A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).2020 ASCO. Abstract 4519
*此文仅用于向医学人士提供科学信息 , 不代表本平台观点
【“ALL 硬”- K药强势“ALL-IN”消化道肿瘤】